0001178913-12-000438.txt : 20120214 0001178913-12-000438.hdr.sgml : 20120214 20120214155542 ACCESSION NUMBER: 0001178913-12-000438 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20120214 DATE AS OF CHANGE: 20120214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: LORUS THERAPEUTICS INC CENTRAL INDEX KEY: 0000882361 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-49893 FILM NUMBER: 12609295 BUSINESS ADDRESS: STREET 1: 2 MERIDIAN ROAD STREET 2: . CITY: TORONTO STATE: A6 ZIP: M9W 4Z7 MAIL ADDRESS: STREET 1: 2 MERIDIAN ROAD CITY: TORONTO STATE: A6 ZIP: M9W 4Z7 FORMER COMPANY: FORMER CONFORMED NAME: IMUTEC PHARMA INC DATE OF NAME CHANGE: 19970113 FORMER COMPANY: FORMER CONFORMED NAME: IMUTEC CORP DATE OF NAME CHANGE: 19950726 FORMER COMPANY: FORMER CONFORMED NAME: RML MEDICAL LABORATORIES INC DATE OF NAME CHANGE: 19920921 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Sweeney Hermon Susan CENTRAL INDEX KEY: 0001542401 FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: 641 ACACIA AVENUE CITY: OTTAWA STATE: A6 ZIP: K1M 0M6 SC 13G 1 zk1211014.htm SC 13G zk1211014.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  10549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. ______)*
­­
 Lorus Therapetics Inc 
(Name of Issuer)

Common Stock 
(Title of Class of Securities)

544192107
(CUSIP Number)
 
November 25, 2011
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
o Rule 13d-1(b)
 
x Rule 13d-1(c)
 
o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 
 
 
 
Cusip No.  544192107
 
1. Name of Reporting Persons/
I.R.S. Identification Nos. of above persons (entities only).
 
Susan Sweeney Hermon
I.R.S. Identification No. – Not applicable
2.
Check the Appropriate Box if a Member of a Group
(a) o
(b) o
3. SEC Use Only
 
4.
Place of Organization
 
Canadian
 
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With:
 
 5.
Sole Voting Power
 
1,078,709
6.
Shared Voting Power
 
0
7.
Sole Dispositive Power
 
1,078,709
8.
Shared Dispositive Power
 
0
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
1,078,709
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
o
11.
Percent of Class Represented by Amount in Row (9)
 
5.0%
12.
Type of Reporting Person :  
 
IN

 
Page 2 of 5 pages
 
 
Item 1.
(a)         Name of Issuer:
 
Lorus Therapeutics Inc.

(b)         Address of Issuer's Principal Executive Offices:

2 Meridian Road, Toronto, Ontario, M9W 4Z7 Canada
Item 2.

              (a)         Names of Persons Filing:

 
This filing statement is being filed by Susan Sweeney Hermon (“Hermon”); and is sometimes referred to as a Reporting Person.

              (b)         Address of Principal Business Office or, if None, Residence:
 
The residence address for the Reporting Person is 641 Acacia Avenue, Ottawa, ON, Canada, K1M 0M6

(c)         Citizenship:
 
Hermon is a Canadian citizen.

(d)         Title of Class of Securities:

Common Stock, no par value

(e)         Cusip Number:

544192107
 
Item 3.          NA
 
Item 4.          Ownership

 
(a)-(c)  The responses of the Reporting Person to items 5 through 11 on the cover page are incorporated herein by reference.  The Common Stock reported herein was previously reported by Hermon’s spouse, William Richard Hermon, who passed away on November 25, 2011, at which time Hermon acquired beneficial ownership or voting or dispositive power over the Common Stock. As of the close of business on November 25, 2011, the Reporting Person’s aggregate beneficial ownership of Common Stock, including an aggregate of 375,510 shares of Common Stock issuable upon the exercise of common stock warrants held by the Reporting Persons, was 1,078,709 shares.  Of this amount, 201,454 shares of Common Stock were held by Hermon directly; 720,735 shares of Common Stock were held by the Estate of William Richard Hermon (the “Estate”) directly; 150,520 shares of Common Stock were held by Gullrock Investments Inc. (”Gullrock”) directly; and 6,000 shares of Common Stock were held by 3780694 Canada Inc. (“3780694”) directly.  The foregoing amounts include: 87,863, 223,517, 62,630, and 1,500 shares issuable upon the exercise of common stock warrants owned by Hermon, the Estate, Gullrock, and 3780694, respectively.
 
 
Page 3 of 5 pages
 
 
 
Hermon exercises sole voting and dispositive power over shares of Common Stock held by each of Hermon, the Estate, Gullrock and 3780694, respectively.

Gullrock and 3780694 are investment holding companies controlled by the Estate, for which Hermon serves as an Executor.
 
Item 5.         Ownership of Five Percent or Less of a Class

 
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.
 
Item 6.         Ownership of More than Five Percent on Behalf of Another Person.

 
NA

Item 7.         Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

See Item 4 above.
 
Item 8.         Identification and Classification of Members of the Group

 
NA
 
Item 9.         Notice of Dissolution of Group

NA
 
Item 10.       Certification

(a)          NA

 
(b)
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 
Page 4 of 5 pages
 

SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:  February 10, 2012
 
  s/ Susan Sweeney Hermon
Susan Sweeney Hermon
 
Page 5 of 5 pages